Lynparza Lowers Risk of Disease Progression in Advanced Ovarian Cancer, 5-year Data Show
When used as a first-line therapy to treat newly diagnosed women with advanced ovarian cancer who previously responded to platinum-based chemotherapy, Lynparza (olaparib) prolonged the time they lived without showing signs of disease progression compared to a placebo, according to five-year data from a Phase 3 trial. Updated findings from the study, called SOLO-1 (NCT01844986), were presented at the recent 2020 European Society of Medical Oncology virtual congress. Lynparza is an anti-cancer therapy jointly developed by AstraZeneca and Merck (known as MSD outside the U.S. and Canada) that has been approved for the treatment of advanced ovarian cancer, pancreatic cancer, and certain types of breast cancer.
Read more from Ovarian Cancer News Today, by Steve Bryson, about Lynparza Lowers Risk of Disease Progression in Advanced Ovarian Cancer, 5-year Data Show